GlobeNewswire by notified

ONE swiss bank opens office in Dubai

Share

14 April 2022

ONE swiss bank expands its activities in the GCC and
makes the opening of its office in Dubai official

ONE swiss bank SA (ONE) is pleased to announce that the acquisition of Falcon Private Wealth Ltd (FPW) has been successfully executed on 29 November 2021. FPW is now a subsidiary of ONE and has been renamed ONE swiss private wealth Ltd* (OSPW). ONE has chosen to communicate now after having taken the time to set up the appropriate structure.

OSPW has been committed to serving its clients in the Middle East and abroad since 2009. Thanks to its boutique size and the agile mindset of its multidisciplinary and multicultural teams, it is able to provide unique and transparent portfolio management and advisory services to high-net-worth individuals and their families, family offices and institutional clients.

Coming together with ONE enables us to confidently look to the future. We will continue to serve our clients with the same dedication and professionalism,and to offer them the very best services, including access to ONE’s proprietary quantitative management and portfolio insurance services provided since 1993 to top-ranking institutional investors, comments Zafar Khan, CEO of ONE swiss private wealth Ltd.

Headquartered in Geneva, Switzerland, and listed on the Swiss stock exchange SIX, ONE is the result of a series of successful mergers. The Bank is a blend of private banking tradition and entrepreneurial spirit in a people-focused structure offering asset management and wealth management services to private and institutional clients. With offices in Geneva, Lugano, Zurich and now Dubai, the Bank manages around CHF 5 billion in assets.

ONE's commitment to the region echoes the bank's strategy to expand its international presence and access fast-growing markets. It also reflects its confidence in the region's economic growth and stability, and in the future of the UAE as a regional and international centre of economic prosperity and business opportunities as Grégoire Pennone, ONE swiss bank’s CEO explains: “This local presence brings us closer to our clients in terms of geographical and cultural proximity and help us to provide them withbespoke investment solutions.We are one of the few Swiss private banks that offer in-depth knowhow in the regional fixed income and equity market and providedirect access to the UAE stock market and new public offerings in the region with Lombard lending facilities.”

Yann Mrazek, Chairman of the Board of Directors of OSPW & Managing Partner at M/HQ adds: “We see a clear similarity in the values that define the Swiss and Dubai financial industries: excellence, stability, discretion and professionalism, to name but a few. Driven by the same values and the desire to achieve a harmonious balance between tradition and innovation, ONEworks tirelessly to offer a new experience in private banking.

* ONE swiss private wealth is an international wealth and asset management firm based in the Dubai International Financial Centre (DIFC) operating under a 3c licence and regulated by the Dubai Financial Services Authority (DFSA).

Media library
ONE swiss bank logo
ONE swiss private wealth logo
Picture of Zafar Khan, CEO, ONE swiss private wealth

For further information, please contact:

Julien Delécraz
Head of Marketing & Communication
jde@oneswiss.com
+41 58 300 78 13

ONE swiss bank SA (SIX Swiss Exchange: ONE)
Listed on the Swiss stock exchange SIX, ONE swiss bank is the result of a series of successful mergers of separate entities that have come together to offer a unique and modern private banking experience. The bank is a blend of private banking tradition and entrepreneurial spirit in a people-focused structure offering asset management and wealth management services to private and institutional clients. ONE has offices in Geneva, Lugano, Zurich and a subsidiary in Dubai. It manages around CHF 5 billion in assets.
oneswissbank.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

ERYTECH to Present at the H.C. Wainwright Global Investment Conference17.5.2022 22:05:00 CEST | Press release

ERYTECHtoPresent at the H.C. WainwrightGlobal Investment Conference Cambridge, MA (U.S.) and Lyon (France), May 17, 2022 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that its Chief Executive Officer, Gil Beyen, will present at the H.C. Wainwright Global Investment Conference. The conference will be held in a hybrid format from May 23-26, 2022, in Miami, USA. The corporate presentation will be held in person on Wednesday, May 25 at 10:30am ET and will be available on-line on the conference website afterwards. Mr. Beyen will be available for one-to-one meetings with investors on May 24, 25 and 26. If you would like to arrange a one-on-one meeting or register, please contact your conference representative. For more information on the H.C. Wainwright 23rd Global Investment Conference, please visit the H.C. Wainwright Conference websi

EVS COMMUNICATES THE RESULTS OF THE ORDINARY GENERAL MEETING17.5.2022 21:59:34 CEST | Press release

Publication on May17, 2022, after market closure Regulated information EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVSCOMMUNICATES THERESULTSOFTHEORDINARYGENERAL MEETING EVS Broadcast Equipment SA, leading provider of live video production systems, held its Ordinary General Meeting on May 17, 2022. In total 73 shareholders representing 2,799,870 shares, or 19.5% of the company shares, attended by proxy the Ordinary General Meeting held physically at the company's registered office but for which the company had recommended its shareholders to attend by videoconference given the still sensitive health situation. All the resolutions have been approved, i.e.: - The remuneration report, the updated remuneration policy, the discharge of the Directors and the Auditor; - The 2021 annual accounts and the allocation of profits, including a total gross dividend of EUR 1.50 for fiscal year 2021 (such dividend is made up, on the one hand, of the i

SeaLegacy Celebrates the Inaugural Year of The Good Ocean17.5.2022 21:49:59 CEST | Press release

A unified, passionate group of businesses investing in SeaLegacy’s mission to protect the world’s oceans British Columbia, Canada, May 17, 2022 (GLOBE NEWSWIRE) -- When eight companies mostly unknown to one another came together for the first time in May of 2021, they were bound only by a commitment to protect our oceans and planet. Today, these founding members of The Good Ocean are actively supporting SeaLegacy’s commitment to ocean protection. "One of the questions I get asked the most is, 'What can I do?'" says SeaLegacy Co-Founder and President Cristina Mittermeier. "This question comes from individuals, and it also comes from businesses. Increasingly, consumers are demanding the products and services they support with their purchasing power be aligned with their desire to be accountable for their impact on earth. Members of The Good Ocean are addressing that demand and stepping into the crucial role businesses play in conservation work. Together, we are taking steps towards syste

Karolinska Development’s portfolio company Aprea Therapeutics acquires Atrin Pharmaceuticals17.5.2022 16:55:38 CEST | Press release

STOCKHOLM, SWEDEN, May 17 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has completed the acquisition of the privately-held US-based biotechnology company Atrin Pharmaceuticals Inc. Aprea Therapeutics will now prioritize the development of Atrin Pharmaceuticals’ drug candidates, which are being developed to fight cancer by affecting the proteins involved in the ability of tumors to repair damage to their DNA. With the acquisition of Atrin Pharmaceuticals’ portfolio of candidate drugs, Aprea Therapeutics intends to shift its primary focus to the development of ATRN-119, a drug candidate that inhibits an important signaling pathway in DNA damage repair. ATRN-119 will soon be evaluated in clinical phase 1/2a studies in the treatment of malignant solid tumors, both as monotherapy and in combination with standard treatment. In parallel with the development of ATRN-119, separate programs are run with a second-generation ATR i

Karolinska Developments portföljbolag Aprea Therapeutics förvärvar Atrin Pharmaceuticals17.5.2022 16:55:38 CEST | Pressemelding

STOCKHOLM, SVERIGE 17 maj 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Aprea Therapeutics har förvärvat det privatägda amerikanska bioteknikbolaget Atrin Pharmaceuticals Inc. Aprea Therapeutics kommer nu att prioritera utvecklingen av Atrin Pharmaceuticals läkemedelskandidater, vilka utvecklas för att bekämpa cancersjukdomar genom att påverka de proteiner som är involverade i tumörers förmåga att reparera skador i sitt DNA. Efter förvärvet av Atrin Pharmaceuticals läkemedelsprojekt flyttar Aprea Therapeutics sitt primära fokus till utvecklingen av ATRN-119, en läkemedelskandidat som hämmar en viktig signaleringsväg vid reparation av DNA-skador. ATRN-119 kommer inom kort att börja studeras i kliniska fas 1/2a-studier vid behandling av maligna solida tumörer, både som monoterapi och i kombination med standardbehandling. Parallellt med utvecklingen av ATRN-119 bedrivs separata program med en andra generationens ATR-hämmare, ATRN-354, med poten